Navigation Links
Notification of Annual General Meeting and Extraordinary General Meeting
Date:6/11/2008

VALLEY COTTAGE, New York, June 11 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) today announced a notice convening its Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM"). The AGM and EGM will take place at the Conference Room at the Company's Israeli offices at Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100, at 4:00 p.m. Israel time, and 4:30 p.m. Israel time, respectively, on July 17, 2008.

At the AGM it is proposed that:

-- the annual report and financial statements for the year ended December

31, 2007 be received;

-- Kesselman & Kesselman (PricewaterhouseCoopers) be reappointed as the

Company's auditors and the fixing of their remuneration be authorized;

and

-- Messrs Michael Weiss, Ben Zion Weiner, William Kennedy, and Laurence

Charney be re-appointed as Directors of the Company.

At the EGM it is proposed that:

-- the grant of options to Michael Weiss and Ben-Zion Weiner as detailed

in the Notice be approved;

-- the grant of options to Ben-Zion Weiner and William Kennedy as detailed

in the Notice be approved; and

-- the remuneration terms for Laurence Charney as detailed in the Notice

be approved.

The Notice of the AGM and EGM is available for the public at the US Securities Exchange Edgar site: http://www.sec.gov/ and at the Israel Securities Authority's site: http://www.magna.isa.gov.il .

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (Nasdaq: XTLB; TASE: XTL).


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification (TAN) Act
2. AMICAS Transforms Critical Results Notification with RadStream
3. Merge Technologies Receives Expected Additional NASDAQ Notification
4. Memory Pharmaceuticals Receives Nasdaq Notification Related to Minimum Bid Price
5. IDM Pharma Receives Notification from NASDAQ Relating to Minimum Bid Price
6. Isolagen, Inc. Receives Notification Letter from American Stock Exchange
7. CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders Equity
8. Delisting Notification Received from the American Stock Exchange
9. PreMD Appeals American Stock Exchange Delisting Notification
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... via seating is proud to ... task chair specifically designed for clinical areas. Genie Copper Mesh is a crossover ... Cupron® to provide customers with a game changing chair that is affordably priced,” ...
(Date:5/26/2017)... ... ... Rob Lowe acts as host and helps educate and inform the public ... American. Viewers can reconnect with America as it explores some of the best places ... looked for an inventive new place for a family vacation, and have discovered hiking. ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “Just What Happened in the Garden of ... in the Garden of Eden” is the creation of published author, Penelope Colt, mother, trader, ... her family moved to NYC when she was three. At six, they moved to ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD ... New York City. He is known for his distinguished expertise and experience in the ... Benvenisty holds sub-specialty training in treating renovascular disease and aortic aneurysm . He ...
(Date:5/24/2017)... ... May 24, 2017 , ... Patients who want to receive cosmetic dentistry ... with Dr. Joseph Bedich for a consultation, with or without a referral. Dr. Bedich ... and functionality. , Dr. Bedich offers a variety of cosmetic dentistry services ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... Ore. , May 9, 2017  Semler ... that provides technology solutions to improve the clinical ... financial results for the first quarter ended March ... our products enable our customers to identify when ... to intervene before events like heart attacks or ...
(Date:5/6/2017)... Texas , May 5, 2017   Provista , ... with more than 200,000 customers, today announced Jim Cunniff ... a wealth of executive and business experience to Provista, including ... compounding pharmacy in California . He assumed ... "Jim is a great fit for Provista," says ...
(Date:5/4/2017)... 2017  Fortuna Fix Inc. (" Fortuna "), a ... to eliminate the need for embryonic and fetal stem cells ... diseases. Fortuna announced today the launch ... Fehlings , MD, PhD; Father Kevin FitzGerald , S.J., ... Professor James Giordano , PhD. "We are ...
Breaking Medicine Technology: